These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 38777812)

  • 21. Autophagy pathway is required for IL-6 induced neuroendocrine differentiation and chemoresistance of prostate cancer LNCaP cells.
    Chang PC; Wang TY; Chang YT; Chu CY; Lee CL; Hsu HW; Zhou TA; Wu Z; Kim RH; Desai SJ; Liu S; Kung HJ
    PLoS One; 2014; 9(2):e88556. PubMed ID: 24551118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pyruvate kinase L/R links metabolism dysfunction to neuroendocrine differentiation of prostate cancer by ZBTB10 deficiency.
    Wen YC; Chen WY; Tram VTN; Yeh HL; Chen WH; Jiang KC; Abou-Kheir W; Huang J; Hsiao M; Liu YN
    Cell Death Dis; 2022 Mar; 13(3):252. PubMed ID: 35306527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of REST Represses the Epithelial-Mesenchymal Transition Process and Decreases the Aggressiveness of Prostate Cancer Cells.
    Indo S; Orellana-Serradell O; Torres MJ; Castellón EA; Contreras HR
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer.
    Cui J; Wang Y; Dong B; Qin L; Wang C; Zhou P; Wang X; Xu H; Xue W; Fang YX; Gao WQ
    Int J Cancer; 2018 Aug; 143(3):645-656. PubMed ID: 29488214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The β
    Braadland PR; Ramberg H; Grytli HH; Urbanucci A; Nielsen HK; Guldvik IJ; Engedal A; Ketola K; Wang W; Svindland A; Mills IG; Bjartell A; Taskén KA
    Mol Cancer Res; 2019 Nov; 17(11):2154-2168. PubMed ID: 31395667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical Models of Neuroendocrine Prostate Cancer.
    Cacciatore A; Albino D; Catapano CV; Carbone GM
    Curr Protoc; 2023 May; 3(5):e742. PubMed ID: 37166213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polycomb-mediated silencing in neuroendocrine prostate cancer.
    Clermont PL; Lin D; Crea F; Wu R; Xue H; Wang Y; Thu KL; Lam WL; Collins CC; Wang Y; Helgason CD
    Clin Epigenetics; 2015; 7(1):40. PubMed ID: 25859291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
    Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
    Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen deprivation‑induced OPHN1 amplification promotes castration‑resistant prostate cancer.
    Liu J; Zhang Y; Li S; Sun F; Wang G; Wei D; Yang T; Gu S
    Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34738630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enzalutamide-Induced Upregulation of PCAT6 Promotes Prostate Cancer Neuroendocrine Differentiation by Regulating miR-326/HNRNPA2B1 Axis.
    Liu B; Jiang HY; Yuan T; Luo J; Zhou WD; Jiang QQ; Wu D
    Front Oncol; 2021; 11():650054. PubMed ID: 34277403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AMPK/SIRT1 signaling through p38MAPK mediates Interleukin-6 induced neuroendocrine differentiation of LNCaP prostate cancer cells.
    Natani S; Dhople VM; Parveen A; Sruthi KK; Khilar P; Bhukya S; Ummanni R
    Biochim Biophys Acta Mol Cell Res; 2021 Sep; 1868(10):119085. PubMed ID: 34171447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TCF7L1 regulates cytokine response and neuroendocrine differentiation of prostate cancer.
    Wen YC; Liu YN; Yeh HL; Chen WH; Jiang KC; Lin SR; Huang J; Hsiao M; Chen WY
    Oncogenesis; 2021 Nov; 10(11):81. PubMed ID: 34799554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroendocrine Differentiation of Prostate Cancer-An Intriguing Example of Tumor Evolution at Play.
    Patel GK; Chugh N; Tripathi M
    Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31547070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis.
    Niu Y; Guo C; Wen S; Tian J; Luo J; Wang K; Tian H; Yeh S; Chang C
    Cancer Lett; 2018 Dec; 439():47-55. PubMed ID: 30227222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting Wnt/EZH2/microRNA-708 signaling pathway inhibits neuroendocrine differentiation in prostate cancer.
    Shan J; Al-Muftah MA; Al-Kowari MK; Abuaqel SWJ; Al-Rumaihi K; Al-Bozom I; Li P; Chouchane L
    Cell Death Discov; 2019; 5():139. PubMed ID: 31583122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blocking the Feedback Loop between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on Prostate Cancer.
    Wang C; Peng G; Huang H; Liu F; Kong DP; Dong KQ; Dai LH; Zhou Z; Wang KJ; Yang J; Cheng YQ; Gao X; Qu M; Wang HR; Zhu F; Tian QQ; Liu D; Cao L; Cui XG; Xu CL; Xu DF; Sun YH
    Clin Cancer Res; 2018 Feb; 24(3):708-723. PubMed ID: 29191973
    [No Abstract]   [Full Text] [Related]  

  • 37. The Neuropilin-1/PKC axis promotes neuroendocrine differentiation and drug resistance of prostate cancer.
    Blanc C; Moktefi A; Jolly A; de la Grange P; Gay D; Nicolaiew N; Semprez F; Maillé P; Soyeux P; Firlej V; Vacherot F; Destouches D; Amiche M; Terry S; de la Taille A; Londoño-Vallejo A; Allory Y; Delbé J; Hamma-Kourbali Y
    Br J Cancer; 2023 Mar; 128(5):918-927. PubMed ID: 36550208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.
    Ragnum HB; Røe K; Holm R; Vlatkovic L; Nesland JM; Aarnes EK; Ree AH; Flatmark K; Seierstad T; Lilleby W; Lyng H
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):753-60. PubMed ID: 24035332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Downregulation of lysine-specific demethylase 1 enhances the sensitivity of hormone-sensitive prostate cancer cells to androgen deprivation therapy.
    Wang M; Liu X; Chen Z; Zhang L; Weng X
    Oncol Lett; 2021 Feb; 21(2):93. PubMed ID: 33376526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Crosstalk Between AR and Wnt Signaling Promotes Castration-Resistant Prostate Cancer Growth.
    Luo J; Wang D; Wan X; Xu Y; Lu Y; Kong Z; Li D; Gu W; Wang C; Li Y; Ji C; Gu S; Xu Y
    Onco Targets Ther; 2020; 13():9257-9267. PubMed ID: 32982312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.